Welcome to our dedicated page for Teva Pharm SEC filings (Ticker: TEVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Teva Pharmaceutical Industries Limited (TEVA) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other key documents filed with the Securities and Exchange Commission. As an issuer with American Depositary Shares listed on the New York Stock Exchange under the symbol TEVA, Teva reports material events, financing arrangements and financial results through these filings.
Recent Form 8‑K filings include items on results of operations and financial condition, where Teva furnishes press releases announcing quarterly financial results for periods such as the quarters ended June 30 and September 30. These filings typically incorporate earnings press releases by reference and clarify that the information is being furnished rather than filed for purposes of the Exchange Act. Another 8‑K describes Teva’s presentation at a major healthcare conference and includes expectations regarding performance for the 2025 fiscal year.
Teva also uses Form 8‑K to disclose material definitive agreements and related direct financial obligations. For example, an 8‑K details the Third Amendment to the Senior Unsecured Sustainability-Linked Revolving Credit Agreement, which extended the maturity date of the revolving facility and amended financial covenants such as the maximum leverage ratio and conditions tied to investment grade status. These filings provide insight into Teva’s capital structure, liquidity management and covenant framework.
On Stock Titan, investors can review these filings alongside AI-powered summaries that explain the main points of each document in plain language. This includes highlighting key terms in credit agreements, summarizing earnings-related disclosures, and pointing out items that may affect leverage, liquidity or future reporting. Users interested in TEVA can use the filings page to track quarterly and annual reporting, current reports on material events, and disclosures related to financing arrangements, while AI tools help interpret lengthy or technical sections of the filings.
Teva Pharmaceutical Industries Limited reports Form 144 sale notices for insider Eric Hughes. The filing lists two transactions: 80,762 ordinary shares sold on 03/03/2026 for $2,613,450.24 and 11,277 ordinary shares sold on 03/04/2026 for $366,102.17. The filing also references 19,654 restricted share units vesting on 03/05/2026.
Teva Pharmaceutical Industries submitted a Form 144 notice reporting a proposed sale of 17,295 ordinary shares (ordinary shares to be sold through Citigroup Global Markets Inc.). The filing lists Richard Daniell as the selling person and shows earlier dispositions in the prior three months: 115,468 shares on 12/09/2025, 128,985 shares on 03/03/2026, and 91,345 shares on 03/04/2026, with corresponding gross proceeds included in the excerpt.
TEVA Pharmaceutical Industries Chief Accounting Officer Amir Weiss exercised 5,179 Restricted Share Units on March 3, 2026, converting them into 5,179 Ordinary Shares at a reported price of $0.0000 per share. Following the conversion, he held 10,829 Ordinary Shares directly and 5,180 restricted share units remain scheduled to vest on March 3, 2027. The restricted share units were originally granted on March 3, 2023, with 5,179 units vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026. The Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.
TEVA PHARMACEUTICAL INDUSTRIES LTD executive Richard Daniell, EVP, Europe Commercial, reported exercising restricted share units and related share sales. On March 3, 2026, he converted restricted share units into ordinary shares at a price of $0.0000 per share through multiple derivative exercises.
He then sold a total of 128,985 ordinary shares in open-market transactions at a weighted average price of $32.3599 per share, with actual prices ranging from $31.72 to $32.865. These sales were made under a Rule 10b5-1 trading plan adopted on November 10, 2025 and include shares sold to cover tax withholding obligations tied to RSU vesting and performance-based awards. Following these transactions, he directly held 123,127 ordinary shares, and certain restricted share units continue to vest, including tranches through March 4, 2027.
Teva Pharmaceutical Industries officer Mark Sabag exercised restricted share units on March 3, 2026, converting 24,900 and 141,478 units into the same number of ordinary shares at $0.00 per share. After these settlements, he directly held 219,206 ordinary shares.
TEVA PHARMACEUTICAL INDUSTRIES LTD reported insider equity transactions by Interim Chief Legal Officer Brian Savage. On March 3, 2026, he exercised 3,461 Restricted Share Units, converting them into 3,461 Ordinary Shares at a stated price of $0.0000 per share.
Following this conversion, he held 4,200 Ordinary Shares, then sold 1,274 Ordinary Shares at a weighted average price of $32.3599 per share to cover tax withholding obligations, leaving 2,926 Ordinary Shares held directly.
Teva Pharmaceutical Industries Ltd reported insider transactions by President and CEO Francis Richard on March 3, 2026. He exercised restricted share units into ordinary shares and then sold a portion of the resulting holdings.
The filing shows exercises or conversions of restricted share units into 67,231 and 891,315 ordinary shares at a stated price of $0.0000 per share, and open-market sales totaling 442,935 ordinary shares at a weighted average price of $32.3599 per share, with individual sale prices ranging from $31.72 to $32.865. The transactions were effected under a Rule 10b5-1 trading plan, and some shares were sold to cover tax withholding obligations related to vesting restricted share units.
After these transactions, Richard directly held 1,121,382 ordinary shares. Footnotes explain that restricted share units were originally granted or earned based on performance and time-based vesting criteria and that each unit represents a right to receive one ordinary share or its cash value.
Teva Pharmaceutical Industries Ltd. executive vice president and chief financial officer Eliyahu Sharon Kalif exercised restricted share units into ordinary shares on March 3, 2026.
He converted 49,800 and 141,478 restricted share units, resulting in 248,756 ordinary shares held directly as of that date.
TEVA PHARMACEUTICAL INDUSTRIES LTD executive Eric A. Hughes reported multiple equity transactions on March 3, 2026. He exercised restricted share units, converting 24,900 and 141,478 units into ordinary shares at a stated price of $0.0000 per share, reflecting vesting and performance-based awards.
Following these conversions, Hughes conducted open-market sales of ordinary shares, totaling 80,762 shares at a weighted average price of $32.3599 per share, with individual sale prices ranging from $31.72 to $32.865. According to the disclosure, part of the sale represented shares required to be sold to cover tax withholding obligations, and the overall transactions were executed under a Rule 10b5-1 trading plan adopted on November 10, 2025.
Teva Pharmaceutical Industries Limited reports a Form 144 notice for proposed sale of 20,461 ordinary shares tied to a restricted share unit award vesting on 03/04/2026. The filing lists Citigroup Global Markets Inc. as the broker and classifies the disposition as compensation-related.